The Oncology Champions (NASDAQ: CSBR) and Genetic Technologies (NASDAQ: GENE) are both small-cap medical businesses, but what is the best business? We will contrast the two companies based on their valuation power, dividends, analyst recommendations, price, ownership of institutions, profitability and earnings.
49.3 per cent of the Champions Oncology shares are owned by institutional investors. In addition, institutional investors hold 2.7 per cent of the stock in Genetic Technologies. Insiders own 44.3 per cent of the Champions Oncology stock.
High institutional ownership is an indicator that large managers of capital, endowments and hedge funds agree that a business is poised for long-term growth.
Volatility and Risk Champions Oncology has a beta of 1.2, which means that their stock price is 20% more unstable than the S&P 500. Genetic Technologies has a beta of 3.71 in contrast, which means that its stock price is 271 per cent more unstable than the S&P 500.
Champions Oncology Champions Oncology logo champion Oncology, Inc. creates and markets technology solutions and products to optimize oncology clinical trials and use in the U.S. It’s Tumorgraft Technology Platform is an approach based on the implantation of human tumours in immune-deficient mice to personalize cancer care. The company provides Customized Oncology Solutions (POS) through its Tumorgraft Software Platform to help physicians create customized treatment options for cancer patients through clot-specific data from drug panels and related customized oncology services. It also offers translational oncology solutions to pharmaceutical and biotechnology companies, including a preclinical Tumorgraft platform. Champions Oncology, Inc. is selling its products to patients and doctors through the Internet, word of mouth, and sales force. Formerly known as Champions Biotechnology, Inc., the company changed its name in April 2011 to Champions Oncology, Inc. to reflect its current focus on developing innovations to optimize oncology drug development and use. Founded in 1985, Champions Oncology, Inc. is headquartered in Hackensack, New Jersey.
